首页> 外文期刊>Modern Pathology >Changes in Galectin-7 and Cytokeratin-19 Expression during the Progression of Malignancy in Thyroid Tumors: Diagnostic and Biological Implications
【24h】

Changes in Galectin-7 and Cytokeratin-19 Expression during the Progression of Malignancy in Thyroid Tumors: Diagnostic and Biological Implications

机译:甲状腺肿瘤恶性进展过程中Galectin-7和Cytokeratin-19表达的变化:诊断和生物学意义。

获取原文
           

摘要

Galectin-7 is associated with p53-dependent onset of apoptosis and proliferation control/differentiation in keratinocyte development. It is also up-regulated in chemically induced rat mammary carcinogenesis. Because the levels of expression of galectin-7 have never been investigated in thyroid tumors (in contrast to those of galectin-1 and -3 associated with malignancy), we initiated analysis of the expression of galectin-7 in benign and malignant thyroid lesions together with that of cytokeratin-19 (CK19), a marker already demonstrated to be useful in diagnosing this kind of lesion. The immunohistochemical expression levels were quantitatively determined by means of computer-assisted microscopy on a series of 84 thyroid lesions including 10 multinodular goiters, 32 adenomas, and 42 carcinomas. Our data clearly indicate a marked down-regulation of galectin-7 expression in a large proportion of adenomas (including the normomacrofollicular, microfollicular, and trabecular variants) if compared with carcinomas. In accordance with results of previous studies, a marked up-regulation of CK19 expression was observed in the thyroid carcinomas, and this contrasted in particular with the low CK19 expression observed in the microfollicular adenomas. Of importance for diagnostic implications, the combination of these two markers enabled our series of microfollicular adenomas (characterized by low galectin-7 and CK19 expression) to be efficiently distinguished from the encapsulated follicular variant of papillary thyroid carcinomas (high galectin-7 and CK19 expression).
机译:Galectin-7与角质形成细胞发展中p53依赖的凋亡和增殖控制/分化的发作有关。在化学诱导的大鼠乳腺癌变中它也被上调。由于从未研究过甲状腺肿瘤中半乳凝素7的表达水平(与恶性肿瘤相关的半乳凝素1和-3的表达相反),我们开始分析半乳凝素7在甲状腺良恶性病变中的表达与细胞角蛋白19(CK19)的标记物一样,该标记物已被证明可用于诊断这种病变。通过计算机辅助显微镜对一系列84个甲状腺病变(包括10个多结节性甲状腺肿,32个腺瘤和42个癌)进行免疫组织化学表达水平的定量测定。我们的数据清楚地表明,与癌症相比,半数腺瘤(包括正常大卵泡,微泡和小梁变体)中的半乳糖凝集素7表达明显下调。根据先前研究的结果,在甲状腺癌中观察到CK19表达的明显上调,这与在微泡腺瘤中观察到的CK19表达低特别相反。对于诊断意义很重要,这两种标记物的组合使我们的微囊腺瘤系列(以低半乳凝素7和CK19表达为特征)与包囊的甲状腺乳头状癌的滤泡变体(高半乳凝素7和CK19表达高)有效区分开来。 )。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号